Epirubicin, in vivo and in vitro Interaction, Erythrocytes, Plasma Proteins In this study, the in vitro interaction of epirubicin (EPR), a cytostatic antibiotic, with plasma proteins (PP), namely a-HSA, y-HSG, a + ß-HSG and with isolated human red blood cells (RBCs) was investigated and further correlated with the in vivo pharmacokinetics and binding of EPR and two of its metabolites, 13-dihydroepirubicin and 7-deoxydoxorubicinone to RBCs. The in vitro encapsulation rate in isolated erythrocytes amounts to 52.9 ± 2.8% and remains constant within the range of studied concentrations (2.5-20 jo,g/ml). EPR was found to bind differently to the various PP in vitro. Binding to a-HSA amounted up to 51.0 ± 7.10%, to a + ß-HSG 79.45 ± 2.7%, to y-HSG 57.1 ± 2.8%. The in v/vo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 ± 6.96%, 11.6 ± 3.1% and 10.05 ± 3.5% respectively, their availability in serum was 42.6 ± 11.8%, 2.4 ± 0.4% and 1.2 ± 0.67% respectively.
In tro d u ctio n
Since it is know n th a t plasm a p roteins can play an effective role as a su b com p artm en t of the blood, it will be extrem ely useful to study the protein bind ing of drugs in o rd e r to o b tain fu rth er inform ation ab o u t its clinical pharm acokinetics and drug distri b ution (C olom bo et al., 1983). B lood com ponents m ay also function as a storage vehicle for drugs, ery throcytes for exam ple possess desirable p roperties of a drug carrier through w hich an intravasal dep o t m ay be achieved (P itt et al., 1983) . Epirubicin, a cytostatic antibiotic from th e anthracycline family rep resents the 4 '-ep im er of doxorubicin. The m ech anism of its an titu m o r activity is sim ilar to th at of doxorubicin which in tercalates into D N A and blocks th erefo re p ro tein synthesis (Yoa-Pu H u et al., 1989) or inhibits the activity of the D N A topoisom erase II (Le B ot et al., 1988) . E P R seem s to have a b e tte r therap eu tic index than doxorubicin, due to its low er m yelosuppressive and low er cardiotoxic effects at equal doses (W eenen et al., 1986) . This can be explained by the Reprint requests to Mag. Suzan Bandak. Telefax: 0043-1-3107210. difference in pharm acokinetics and m etabolism revealing a low er half-life of elim ination for E P R due to a unique glucuronidation pathw ay in hum an (Van d er Vigh et al., 1990) . D ue to the fact th at R BCs play an active role in drug distribution, m etabolism and elim ination it was necessary to carry out this study to investigate how far R B C s do interfere in the distribution and m etabolism of E PR . The m echanism of interaction betw een E P R and R B C s m ight be an electrostatic one, sim ilar to th at of doxorubicin (Suillerot et al., 1988) and/or interaction with the lipid com ponents of the R B C m em brane. The fact th a t m etabolites were found in RB C s indicates p en etratio n of E P R inside the RB C s and thus supposing the presence of lipid areas inside the blood cells.
Two m etabolites w ere detected with the system we applied, 13-dihydroepirubicin and 7-deoxy doxorubicinone. 13-D ihydroepirubicin is form ed through reduction of the C 13 carbonyl function by an aldoketo reductase, 7-deoxy-doxorubicinone through reductive and hydrolytic cleavage of the am ino sugar m oiety to yield the an th raq u in o n e aglycone (R obustelli, 1989) as shown in Fig. 1 .
The 13-dihydro m etabolites of the anthracyclines are generally considered as active as the p a r ent com pound in contrast to the inactive aglycones 0939-5075/94/0700-0483 $ 06.00 © 1994 Verlag der Zeitschrift für Naturforschung. All rights reserved.
or glucoronides (Schott and R o b ert, 1989) . H ow ever, very few d ata are available on th eir activity.
M aterials and M ethods

C hem icals
E pirubicin hydrochloride (Farm orubicin 2 mg/ ml) was supplied as a lyophilized pow der for injec tion, by Farm italia C arlo E rb a A G (V ienna, A us tria), 13-dihydroepirubicin and 7-deoxydoxorubicinone w ere supplied by Farm italia C arlo E rb a A G (M ilano, Italy). Isoton II was obtained from Heilige (G erm any). E rythrocyte con cen trate from hum an volunteers was kindly supplied by the sur gery d ep artm en t o f th e H ospital R udolfstiftung (V ienna).
All reagents w ere of H P L C grade: m ethanol LiChrosolv, M erck (D arm stad t, G erm any), bidis tilled w ater, crist. potassium dihydrogen phos phate, R iedel-de H aen A G (H annover, G erm any), disodium hydrogen phosphate, M erck (D a rm stadt, G erm any).
The PP, a -H S A (9 6 -9 9 % album in), y-H SG (99% ) and a + ß-H SG were obtain ed from Sigma C hem ical Co. (St. Louis, U.S.A.). For the separation of the proteins C entrisarts ultrafiltration tubes with a M W C O of 10,000 from Sartorius A G (G öttingen, G erm any) w ere used.
C hrom atography
The am ount of E P R was determ ined using a high perform ance liquid chrom atographic m ethod as described (Czejka and G eorgopoulos, 1988 ) and which we fu rther modified. The system used con sisted of solvent delivery system M odel 420 Kontron (A ustria), an autom atic au tosam pler injector M odel 460 K ontron (A ustria), Shim adzu RF-551 fluorim etric detector Shim adzu (Japan), a N ucleosil C18 colum n (5 pm), length 12.5-0.5 cm and a W &W recorder m odel 312. The fluorim etric d e tection followed at an excitation w avelength of 480 nm and an emission of 560 nm , with a range of x 4 and gain x4. The system was o p erated at a flow rate of 1 ml/min, 110 b ar pressure and 22 °C adjusted by a colum n oven 830 K ontron (A ustria).
Sam ple clean up
Bond Elut C 18 cartridges (packing volum e 100 mg, 30 pm m ean particle diam eter) Varian A nalytichem (V ienna) w ere used for solid phase extraction. The extraction p ro ced u re was carried out by use of a vacuum extractio n unit from Vac E lut A nalytichem Int. (U.S.A.).
U ltrafiltration
P reparation o f erythrocytes: H eparinized fresh hum an blood was centrifuged at 1500xg for 20 m in at 4 °C and the plasm a was separated (Zocchi et a l, 1989). The erythrocytes were w ashed three tim es with an Isoton II solution, pH 7.4 and resuspended in Isoton II in the ratio 1:2.5 to yield a h aem ato crit of 0.4. 1) B in din g to erythrocytes: 900 |il of the w ashed erythrocytes w ere spiked with 100 ^1 E P R in Iso ton II (pH 4). The tubes w ere k ep t under p ro tec tion from light for 0, 15, 30, 60 and 120 min in a Techne D ri-B lock DB-1 at 37 °C in order to d e te r m ine the tim e dependency of the encapsulation. Following co ncentrations of E P R w ere m easured: 2.5, 5.0, 10 and 20 jig/ml. T hree experim ents were carried out with each concentration. Solutions of E P R in Isoton II w ere handled under identical conditions for control. A fter incubation the sam ples w ere centrifuged for 5 min at 4000 x g using a L abofuge I H eraues, C hrist (A ustria). The su p e r n a ta n t was th en rem oved and ch rom atographed as described previously.
2) B in din g to p la sm a protein s: Physiological co n centrations of th e PP in buffer solution (19.7 ml 0.9% K H 2P 0 4 and 80.3 ml 1.2% N a2H P 0 4, pH 7.4) a-H S A , a + ß-H SG : 4 g/100 ml, y-H SG 1 g/ 100 ml w ere freshly p rep ared as given in the litera tu re (C iba G eigy Tables, 1979) . The ultrafiltratio n m em brane of the tubes was purified with distilled w ater fo r 20 min from a d h e re n t contam inants. The m em b ran e was then p reconditioned for 5 min (until saturation) with the solution which had to be ultrafiltered. In ac cordance to the R B C s th e following concen trations of E P R solution w ere m easured: 2.5, 5.0, 10 and 20 jig/ml. 900 ^1 protein solution was spiked with 100 ^il E P R solution and k ep t at room te m p era tu re for 30 min. T hree experim ents w ere car ried o ut with each concentration. A fter various in cubation tim es 15, 30, 60 and 120 min sam ples w ere centrifuged for 5 min at 4000x g and the su p ern atan t was analyzed as described.
3) In v iv o bin din g to RB CS: E P R was injected as an i.v. bolus (60 m g/m 2) over 2 m in in four patients suffering from colorectal cancer. M ean dose E P R injected was 110 ± 5.80 mg. Blood sam ples w ere drawn from patients after 5 min of injection, w hen a-phase of E P R distribution from blood and tis sues into blood subcom partm ents has been te r m inated. Sam ples w ere centrifuged at 2500x g for 5 min. E P R concentration was determ ined in serum and in RBCs.
Solid p h a se extraction
The RP-18 extraction cartridges w ere p reco n ditioned thrice with 1 ml of m ethanol and con ditioned with 2 ml p h o sphate buffer (pH 4.0). 1 ml erythrocyte suspension was lysed with 1 ml of distilled w ater and centrifuged at 4000 r.p.m. The su pernatant was then w ashed with m ethanol/buf fer. E P R was extracted from the su p ern atan t and serum with 1 ml m ethanol/phosphate buffer and analyzed.
B iom etric calculations
As know n, there exists a balance betw een free, R B C -bound and PP-bound drug concentration in the blood (D e re n d o rf and G a re tt, 1987). T h ere fore the given coefficient of R B C partitioning defines the ratio betw een bound and free plasm a drug concentration as in Eqn. (1):
The w hole am ount of E P R in serum was d e te r m ined according to Eqn. (2): 100% E P R ser = % E P R free + % E P R rbc + % M l + % M 2 + % M 1 rbc + % M 2 rbc + EPR pp .
Besides, the distribution of the m etabolites in RBCs form ed in the liver should be considered.
R esults and D iscussion
Protein and R B C binding of a drug represents an im portant factor of its serum pharm acokinetics due to distribution into subcom partm ents of the blood. A nyhow through binding to RB C s and/or PP a re ta rd ed circulation of the drug results, which is undesirable with anthracyclines due to the p e r m anent cardiotoxicity of the circulating drug. In the present study we w anted to elucidate the ex tent of E P R and its m etabolites binding to R BCs and PP, which is still up till now n o t investigated. D ifferences in binding to PP are due to i) a dif ference in the concentration of binding protein, ii) a difference in th e characteristics of the b ind ing p ro tein itself (binding site, binding affinity) (Taeyuki et al., 1991) , iii) the chem ical structure of the drug.
The ultrafiltratio n m ethod results lead to the conclusion th a t E P R binds definitively and rapidly to PPs and hum an R B C s in vitro as well as in vivo. Sam ple clean up recovery of E P R was 97% , of 13-dihydroepirubicin 94% , of 7-deoxydoxorubicinone 88% and the absolute sensitivity 1 ng/ml. A m ong the studied protein fractions, a + ß-H SG showed an unexpectedly high binding of 79.45 ± 2.7% to E P R , although this fraction m ainly binds basic drugs. This is explicable by the fact th at E P R may exist in an ionized form in blood having a pK a value of 8.2 for the hydrochloride (Vigevani and W illiam son, 1980) . B inding to a -H S A am ounted up to 51.0 ± 7.10% , and to y-H SG 57.1 ± 2.8% as shown in Fig. 2 . The in vjYro-binding rate to RBCs seem s to vary w ithin a constant range of 52.9 ± 2.8% w ith a hem atocrit of 0.4. Table I shows the coefficients of partitio n for PP and R B C s in vitro. The in vitro interaction of E P R Results did not show any significant difference to those experim ents carried o ut at 37 °C. Binding to a-H S A was found to be 52.4 ± 5.5% , to a + ß-H SG 76.1 ± 4.2% , to y-H SG 59.5 ± 3.8% and to RBCs 54.6 ± 5.0%.
E P R shows a rapid distribution phase (a-p h ase) within the first 20 min, with half-life of 3 min (Eksborg, 1990) , followed by an interm ediate re equilibration phase (ß-phase) and a third phase of term inal elim ination. Blood sam ples w ere draw n after 5 min of injection, because at this tim e point the distribution phase a is term in ated and E P R can be found in serum and RB C s at high concen trations, before elim ination and actual bio tran s form ation take place. 13-D ihydroepirubicin (Ml) and 7-deoxydoxorubicinone (M 2) w ere detectable in serum and RBCs. The m etabolites ap p ea r al ready within 5 min after injection, bo th in serum and RBCs, indicating thus a vivid bio tran sfo rm a tion process for E PR . 42.6 ± 11.8% of E P R was found unbound in serum , 32.0 ± 6.9% was bound to RBCs and the rest was eith er bound to plasm a proteins or m etabolized. Table II giving in the to tal 100% E P R as shown in Eqn. (2).
The concentration of the m etabolites in RB C s is higher than in serum . The K RBC for M l after 5 min of injection was 4.83, for M 2 8.0, indicating thus a very high affinity of the m etabolites in serum to RB C s or a m etabolizing process inside the erythrocytes. The very high K RBC for M 2 is due to its higher lipophilicity through its loss of the am ino sugar group, and th erefo re m ore intensive interactions betw een it and the lipophilic R B C That the in vitro EPR binding to RBC about 1.6-fold higher than in vivo is due to the fact that metabolizing enzymes, proteins and hepatic excre tion are absent in vitro. The encapsulation or bind ing of EPR was completely fulfilled within 5 min, both in vivo and in vitro experiments. No m etabo lites were detected under in vitro conditions. De Loach et al. proved that the concentrations of doxorubicin higher than 3 mg/ml has a great influ ence on the am ount of drug that can be encapsu lated in RBCs (Magnani and Loach, 1992 ) the fact that we did not further investigate.
Extent o f in vivo PP binding
It has been shown for some drugs that the extent of PP binding can be estim ated using KRBC, al though this m ethod is only applicable at high nontherapeutical concentrations (M arroum and Curry, 1993) . The in vivo binding to PP can be calculated as follows:
where / = fraction of free drug.
The in vivo extent of protein binding was deter mined at a concentration of 1188.5 ± 702.26 ng/ml EPR in serum, resulting in a binding rate of 33.6%. Anyhow, although this method may not be applicable for anthracyclines, the result obtained can be in all cases reasonable as 42.6% of EPR was found unbound in serum and 32.0% bound to RBCs. Mean value of the in vitro binding of EPR to all PP studied fractions summed up to 62.5 ± 12.22%. As already mentioned, this difference in binding is caused by metabolizing processes, bind ing to other fractions (RBCs) and an assumed inactivation of EPR at blood pH 7.4.
Conclusions
The in vivo and in vitro determ ination of EPR in subcom partm ental structures of blood allows to obtain further detailed information about the amount of EPR bound to tissues and the amountfree circulating in blood. Binding of EPR to PP and to RBCs is therapeutically not desirable, due to the resulting intravasal depot and the retarded circulation in organism. EPR undergoes a partial metabolic activation in blood through the form a tion of the dihydrometabolite. The use of RBCs in drug targeting as De Loach propagated for doxo rubicin, may be useful just in the case the loaded RBCs can be transferred to the "site of action". However, this transfer action cannot be predicted, because it depends on the kind, stage and metastasization of the tumor. Encapsulation m ethods in RBCs in order to attain a better drug targeting were successfully achieved with antibiotics, such as gentamycin and anticoagulants, due to the en hanced RBCs concentration in the tum or area. It is still unforeseeable whether RBCs will prevail as drug carriers. Anyhow, RBCs should not be affected or damaged by the drug.
On the other hand, the present results show that PP and RBCs certainly act as a transport vehicle within the blood. Besides, the metabolization of EPR in RBCs should not be underestim ated, as long as some of the formed metabolites, 7-deoxydoxorubicinone and glucuronides, are therapeuti cally insignificant and therefore contribute to the inactivation of EPR. These results are similar to those which we already observed with doxorubi cin. In further experiments, the combination of EPR with biomodulating agents, for example interferon a will be examined relating to differ ences in metabolism, serum pharmacokinetics and distribution in subcom partm ental structures.
